Leech Extract Anti-Atherosclerotic Pharmacology
Leech-extract anti-atherosclerotic pharmacology (composite topic entry; no single primary publication attributed).
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- Expert consensus
- Drug vs leech
- Leech-derived crude extract
- Safety domains
- Bleeding
Clinical translation limit
Review evidence does NOT establish clinical efficacy for atherosclerosis prevention or treatment. Atherosclerosis is not an FDA-cleared K040187 indication.
Molecular Profile
- Category
- Other
- Evidence tier
- Preclinical
- Source species
- Hirudo medicinalis (composite)
Biological Targets
- → platelet aggregation; endothelial inflammation; fibrinogen; serum lipids
External Resources
Related Other Compounds
Granulin (leech-derived)
Growth factor and wound-healing modulator — promotes angiogenesis and tissue regeneration.
Leech VEGF Modulator
Vascular endothelial growth factor pathway modulator — angiogenic and wound-healing implications.
Leech PDGF Modulator
Platelet-derived growth factor pathway modulator — implications for wound-healing.
Leech Granulin-A
Granulin-family peptide identified in Hirudo medicinalis — putative growth-factor / wound-healing analog (mechanistic only).